Abstract
Background: The study model of chronic musculoskeletal inflammatory pain, Rubiadin [1,3-dihydroxy-2-methylanthracene-9,10-dione] choice of a drug aimed to evaluate the anti-hyperalgesic effects. Objective: To induce gastrocnemius muscle-stimulated hyperalgesia, 3 % carrageenan was injected intraperitoneally. Methods: The response to heat and mechanical stimuli was monitored for 9 days. The effect of 1st dose of rubiadin start monitoring after the 14th day of carrageenan injection and continued monitoring up to the 22nd day. After the administration of rubiadin intraperitoneally, the antihyperanalgesic activity was observed. Results: Furthermore, increasing the temperature and mechanical threshold supports histopathological observations with extreme reduction in prostaglandin E2 (PGE2) level. Conclusion: The objective is to observe anti-inflammatory and anti-hyperalgesic activity of rubiadin in a pain model that is initiated via supraspinal or spinal neuronal mechanisms, predominantly by inhibition of PEG2. Rubiadin provides a wide range of activities in the treatment of chronic muscle pain and chronic muscular inflammation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
